Related Experiment Video
Updated: May 29, 2026
09:58
Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Lipoprotein a levels in pediatric migraine
Serap Teber1, Ömer Bektas, Arzu Yılmaz
1Department of Pediatric Neurology, School of Medicine, Ankara University, Turkey. bektasomer@gmail.com
Pediatric Neurology
|September 13, 2011
Summary
Children with migraine show higher lipoprotein (a) [Lp(a)] levels, suggesting a potential link between childhood migraine, elevated Lp(a), and stroke risk.
Area of Science:
- Neurology
- Cardiovascular Science
- Pediatrics
Background:
- Migraine is a common neurological disorder.
- Elevated lipoprotein (a) [Lp(a)] is a known risk factor for stroke.
- A potential link between migraine and stroke via Lp(a) is being investigated.
Purpose of the Study:
- To investigate lipoprotein (a) [Lp(a)] levels in children diagnosed with migraine.
- To explore the possible association between high Lp(a) levels and migraine in pediatric patients.
- To determine if elevated Lp(a) could be a factor connecting childhood migraine to stroke risk.
Main Methods:
- Plasma Lp(a) levels were measured in 63 pediatric migraine patients and age-matched controls.
- Statistical analysis was performed to compare Lp(a) levels between the groups.
- Prevalence of elevated Lp(a) levels (>30 ng/mL) was assessed in both groups.
Main Results:
- Migraine patients exhibited significantly higher mean Lp(a) levels (17.09 ± 12.12 ng/mL) compared to controls (10.36 ± 10.41 ng/mL).
- Median Lp(a) levels were also significantly higher in the migraine group (77.62 ng/mL) versus the control group (49.38 ng/mL).
- A higher percentage of migraine patients (19%) had Lp(a) levels >30 ng/mL than controls (6.3%).
Conclusions:
- This study provides evidence of elevated Lp(a) concentrations in children experiencing migraine.
- High Lp(a) levels in pediatric migraineurs may represent a novel link between migraine and stroke.
- Further research is warranted to elucidate the role of Lp(a) in the pathophysiology of childhood migraine and associated stroke risk.
Related Concept Videos
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...